Coloplast A/S

LSE:0QBO Stock Report

Market Cap: DKK 200.4b

Coloplast Valuation

Is 0QBO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QBO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QBO (DKK890) is trading below our estimate of fair value (DKK1443.15)

Significantly Below Fair Value: 0QBO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QBO?

Key metric: As 0QBO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QBO. This is calculated by dividing 0QBO's market cap by their current earnings.
What is 0QBO's PE Ratio?
PE Ratio39.7x
EarningsDKK 5.05b
Market CapDKK 200.37b

Price to Earnings Ratio vs Peers

How does 0QBO's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QBO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.9x
CTEC ConvaTec Group
40.4x20.5%UK£4.9b
AMS Advanced Medical Solutions Group
39.5x23.0%UK£439.9m
TSTL Tristel
32.3x17.5%UK£209.7m
SN. Smith & Nephew
35.3x22.5%UK£8.6b
0QBO Coloplast
39.7x12.9%DKK 200.4b

Price-To-Earnings vs Peers: 0QBO is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the peer average (36.9x).

Price to Earnings Ratio vs Industry

How does 0QBO's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0QBO 39.7xIndustry Avg. 28.9xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QBO is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0QBO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QBO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.7x
Fair PE Ratio38.5x

Price-To-Earnings vs Fair Ratio: 0QBO is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the estimated Fair Price-To-Earnings Ratio (38.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QBO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 890.00
DKK 923.24
+3.7%
9.3%DKK 1,030.00DKK 700.00n/a21
Nov ’25DKK 872.60
DKK 913.33
+4.7%
11.0%DKK 1,050.00DKK 700.00n/a21
Oct ’25DKK 879.49
DKK 913.60
+3.9%
11.0%DKK 1,060.00DKK 700.00n/a20
Sep ’25DKK 923.69
DKK 911.35
-1.3%
11.3%DKK 1,060.00DKK 700.00n/a20
Aug ’25DKK 898.15
DKK 905.90
+0.9%
11.0%DKK 1,060.00DKK 710.00n/a20
Jul ’25DKK 837.11
DKK 895.40
+7.0%
10.5%DKK 1,060.00DKK 710.00n/a20
Jun ’25DKK 818.86
DKK 909.89
+11.1%
10.2%DKK 1,060.00DKK 710.00n/a19
May ’25DKK 842.75
DKK 917.05
+8.8%
10.9%DKK 1,060.00DKK 700.00n/a19
Apr ’25DKK 929.56
DKK 897.32
-3.5%
10.3%DKK 1,060.00DKK 700.00n/a19
Mar ’25DKK 911.42
DKK 871.79
-4.3%
10.1%DKK 1,000.00DKK 700.00n/a19
Feb ’25DKK 799.42
DKK 823.74
+3.0%
9.8%DKK 962.00DKK 631.00n/a19
Jan ’25DKK 772.00
DKK 816.56
+5.8%
10.3%DKK 962.00DKK 631.00n/a18
Dec ’24DKK 795.52
DKK 817.67
+2.8%
10.1%DKK 962.00DKK 631.00n/a18
Nov ’24DKK 744.07
DKK 848.78
+14.1%
9.2%DKK 980.00DKK 686.00DKK 872.6018
Oct ’24DKK 747.60
DKK 865.24
+15.7%
9.9%DKK 1,000.00DKK 686.00DKK 879.4917
Sep ’24DKK 792.36
DKK 907.53
+14.5%
10.1%DKK 1,070.00DKK 720.00DKK 923.6915
Aug ’24DKK 827.11
DKK 928.88
+12.3%
9.9%DKK 1,070.00DKK 720.00DKK 898.1516
Jul ’24DKK 853.19
DKK 915.44
+7.3%
11.0%DKK 1,070.00DKK 690.00DKK 837.1116
Jun ’24DKK 873.87
DKK 915.44
+4.8%
11.0%DKK 1,070.00DKK 690.00DKK 818.8616
May ’24DKK 970.77
DKK 912.94
-6.0%
10.0%DKK 1,045.00DKK 690.00DKK 842.7516
Apr ’24DKK 901.80
DKK 902.63
+0.09%
9.8%DKK 1,045.00DKK 690.00DKK 929.5616
Mar ’24DKK 803.72
DKK 903.13
+12.4%
10.2%DKK 1,045.00DKK 690.00DKK 911.4215
Feb ’24DKK 838.42
DKK 907.33
+8.2%
9.7%DKK 1,045.00DKK 690.00DKK 799.4215
Jan ’24DKK 816.00
DKK 918.87
+12.6%
7.7%DKK 1,045.00DKK 798.00DKK 772.0015
Dec ’23DKK 861.05
DKK 937.00
+8.8%
11.4%DKK 1,224.00DKK 798.00DKK 795.5214
Nov ’23DKK 841.48
DKK 948.29
+12.7%
12.2%DKK 1,224.00DKK 790.00DKK 744.0714

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Guerbet

€339.2m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€27.00

7D

-9.8%

1Y

50.2%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.92

7D

-4.8%

1Y

-9.6%

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.06

7D

-6.1%

1Y

5.3%